Medicare Will Cover Avastin Despite FDA Ruling

Law360, New York (June 30, 2011, 8:14 PM EDT) -- The Centers for Medicare and Medicaid Services said Thursday that Roche Holding Ltd.'s drug Avastin will continue to be covered by Medicare for breast cancer treatment, despite a negative recommendation by the U.S. Food and Drug Administration.

After a two-day hearing, an FDA advisory panel voted Wednesday to yank approval for use of drug, made by Roche subsidiary Genetech Inc., in treating breast cancer patients. The recommendation prompted concerns that Medicare and other insurers would cease coverage for the drug, which Roche and Genetech say remains...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.